AEterna Zentaris Inc. (AEZS)

[skitahoe]

Given AEZS's financial situation I'll agree that a partnership for AEZS-120 is good news. However, all investors need to recognize that the longer you hold a drug that's producing positive results through clinical trials, the more you can ask for in partnering the drug.

That said, GNVC is in a similar situation with their hearing drug, but if successful it could be worth a fortune to them. Perhaps we'll get more details on this agreement when quarterly results are discussed. If like GNVC, the royalty rate could grow to low double digit percentages if sales meet the highest milestone level, this could make a lot of money for AEZS.

AEZS is clearly undervalued, but investors are waiting for news. I believe we'd all like to hear a plan from management on how the share price should exceed $1 before the Nasdaq deadline, as well as a commitment on how long they'll hold off on doing a R/S if they haven't achieved $1. Personally I believe they intend to do the R/S after they report all warrants have converted to stock and just how high the O/S is. I hope I'm wrong about this.

Gary